Bibliography
- BROMME D, KALETA J: Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Carr: Pharm. Des. (2002) 8(18):1639–1658.
- ••Up-to-date review of developments in thecathepsin field.
- SMITH WW, ABDEL-MEGUID SS: Cathepsin K as a target for the treatment of osteoporosis. Expert Opin. Ther: Patents (1999) 9(6):683–694.
- ••Clearly provides the rationale for targetingcathepsin K.
- VILLADANGOS JA, BRYANT RA, DEUSSING J et al.: Proteases involved in MHC class II antigen presentation. Immunol. Rev (1999) 172:109–120.
- RIESE RI, CHAPMAN HA: Cathepsins and compartmentalization in antigen presentation. Curr: Opin. Immunol. (2000) 12(1):107–113.
- MISSBACH M: Selective cathpsin K inhibitors. Proceedings of the 3rd RSC-SCI Symposium on Proteinase Inhibitor Design. London, UK (May 2002).
- CLISSOLD C, PEREZ VMD: Synthesis of furanone-containing ligands with high binding affinity for the cysteine protease cathepsin S. Drugs of the Future (2002) 27\(Supp1.4214.
- PODOLIN PL, CAPPER EA, BOLOGNESE BJ et al: Cathepsin S inhibitors block invariant chain processing and antigen-induced proliferation in vitro, and inhibit murine collagen-induced arthritis (CIA) and rat ovalbumin-induced asthma in vivo. Inflation. Res. (2002) 51\(Supp1.2):Abst.76.
- SPERO DM, WARD YD, THOMSON D et al: Design and synthesis of novel cathepsin S inhibitors. 224th ACSMeeting. Boston, USA (18 — 22 August 2002) MEDI 10.
- WARD YD, THOMSON DS, FRYE LE et al: Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors. J. Med. Chem. (2003) 45:5471–5482.